Khaberni - A trial drug reduced triglyceride levels by approximately 40%, and more than 60% for those with higher baseline levels, after just 14 days of treatment.
The drug, named TLC-2716, targets fat production in the liver and intestines, avoiding issues that hindered previous attempts to develop similar medications.
A small and short French trial conducted at the University of Lausanne showed no serious side effects, but larger and longer studies are needed to prove the drug's safety and effectiveness in preventing heart diseases.
Cholesterol
According to "Study Finds", the level of remnant cholesterol, a dangerous type of blood fat linked to heart attacks, dropped by about 61% post meals for those taking higher doses.
Millions worldwide take statins to lower cholesterol, but many still have high and dangerous levels of triglycerides and other blood fats that statins do not treat.
Now, a trial drug successfully reduced these hard-to-treat fats by up to 60% in a small, early-stage trial, potentially offering hope for those still at high risk of heart disease despite standard treatments.
The drug TLC-2716 targets a molecular key in the liver that controls fat production.
Effective over a short period
After just 14 days of taking the pills daily, participants noticed a significant decrease in levels of triglycerides and remnant cholesterol, a harmful type of blood fat associated with artery blockage and heart attacks, even while controlling harmful cholesterol (LDL) levels.
What stood out was the drug's effectiveness in those who had elevated levels of triglycerides. The highest dose reduced these fats by more than 60%. This is a significant change over such a short study period.
